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Abstract Calcium fructoborate (CF), a natural sugar-borate
ester found in fresh fruits and vegetables, is a source of soluble
boron. CF contains three forms of borate (diester, monoester,
and boric acid) and all are biologically active, both at the
intracellular (as free boric acid) and extracellular level (as
fructose-borate diester and monoester). At the cellular and
molecular level, CF is superior to the boric acid/borate,
exhibiting a complex Bprotective^ effect against inflammatory
response. CF is commercially available in the USA as a
Bnature-identical^ complex, an active compound for dietary
supplements. It provides effective and safe support against the
discomfort and lack of flexibility associated with
osteoarticular conditions (arthritis and joint degeneration),
and improves Western Ontario and McMaster Universities
Osteoarthritis (WOMAC) and McGill indexes. In addition,
orally administered CF is effective in ameliorating symptoms
of physiological response to stress, including inflammation of
the mucous membranes, discomfort associated with osteoar-
thritis disorders, and bone loss, and also for supporting car-
diovascular health. Clinical studies have exhibited the ability
of CF to significantly modulate molecular markers associated
with inflammatory mechanisms, mainly on the elevated serum
levels of C-reactive protein (CRP).
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Introduction
Calcium fructoborate (CF), a sugar-borate ester (SBE), is the
most scientifically studied boron-based dietary supplement,
with over a dozen of published studies on its unique chemical
and clinical properties [1].
SBEs are found in fruits, vegetables, certain nuts, and le-
gumes, and they are naturally absorbed by animal cells [2]. CF
is the most common SBE, typically manifesting as the specific
bis-fructose ester. In foods, they thus serve as a source of
soluble borate. Currently, CF is manufactured as a Bnature-
identical^ complex [3] and is commercially marketed as
FruiteX-B® Brand calcium fructoborate (FrXB). Although
calcium fructoborate is naturally occurring and found in com-
monly ingested fruits and vegetables, the commercially pro-
duced FrXB calcium fructoborate complex is formed by a
proprietary reaction of boric acid with fructose and calcium
carbonate [3]. FrXB is used as an active component of dietary
supplement products in the USA for bone health and for mod-
ulation of the symptoms of arthritis and joint degeneration,
justified by its reported clinical potency to reduce inflamma-
tion, and to improve Western Ontario and McMaster Univer-
sities Osteoarthritis (WOMAC) and McGill indexes [4, 5].
According to some recent clinical trials, FrXB can also be
used to prevent cardiovascular disorders [6, 7].
Intake, Occurrence, Chemistry, and Nutritional
Significance of Calcium Fructoborate
Intake and Occurrence
The bis-fructose ester of boric acid has been detected in plants,
fruits, seeds, honey, and some foodstuff (Table 1); it is clear
that fructoborate ester is a naturally occurring part of the hu-
man diet [Scorei et al., unpublished data]. Thus, the mean
daily intake of fructoborate and related complexes is estimated
to be about 35 mg (1.05 mg B), and the 95th percentile intake
is estimated at about 75 mg (2.25 mg B) [1, 8]. In accordance
with the BDietary Reference Intakes^, in the USA boron-
based compounds regulated as dietary supplements may pro-
vide up to 20 mg of elemental boron equivalents per day [9].
Recently, a simple, fast, specific, and precise high perfor-
mance thin layer chromatography (HPTLC) and colorimetric
methods have been developed and validated for the esti-
mation of boron as boric acid, borax, and sugar-borate
esters as calcium fructoborate esters (CFEs) in foodstuff
and dietary supplements [10, 11].
Chemistry
The results of the thermal analysis, together with those of X-
ray powder diffraction (XRD), Fourier Transform Infrared
(FTIR) spectroscopy, and Raman spectroscopy, led to the con-
clusion that FrXB is a natural identical product with following
molecular composition Ca[(C6H10O6)2B]2°4H2O, identical
with the CF molecule found in nature, containing 2.5
±0.1 % boron and 4.6±0.1 % calcium [12]. Other research
has identified those three basic types of boron-containingmol-
ecules in aqueous solutions of FrXB: free boric acid, the di-
ester complex, and the monoester complex. The relative molar
concentrations of these three types of boron-containing mole-
cules were found to be approximately 5, 85, and 10%, respec-
tively [13].
Nutritional Significance
The significance of boron nutrition in the prevention of chron-
ic disease has been recognized for some time in the global
community [14, 15]. Symptoms of boron deficiency are
non-specific, including arthritis, bone loss, decreased immu-
nity, and osteoporosis [15–17]. In developing countries, bo-
rate supplementation may be effective for the prevention of
osteoarthritis and osteoporosis [4, 5, 18], prostate [2, 19] and
breast cancer [20], cardiovascular diseases [6], and recently, as
an adjunct treatment for osteochondrosis in animals and
humans [21]. Furthermore, boron was not found to be associ-
ated with the collagen matrix but almost entirely and exclu-
sively located within the mineral portion of bone [22]. Boron
is suggested to affect bone mineral by influencing serum ste-
roid hormone levels (estrogen and testosterone) and the me-
tabolism and utilization of calcium [23–25] and other mineral
elements of bone [17, 25]. Furthermore, boron levels in bone
and blood increasing with age and health state and decreased
with disease conditions [1, 7, 8, 14, 18, 22, 25].
SBEs are regular components of the human diet found in
vegetables and fruits that have previously been considered
non-essential for human health. In the last decade, however,
they have become the subject of intensive investigations be-
cause of their possible beneficial effects. Our results indicate
Table 1 Content of total boron and fructoborate esters in various
foodstuff (average values)




Dandelion root (Taraxaci radix) 200 80
Honey (mel) 12 7




Tomato paste 20 7
Fructose 80 80
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that calcium fructoborate (the most common SBE), may ex-
hibit a Bprotective^ effect against inflammatory molecules at
cellular and enzymatic levels [6, 7, 20, 26–28]. Calcium
fructoborate, as a naturally occurring boron dietary derivative,
serves as an important source of bioavailable dietary borate
storage and, when administered orally, is effective in amelio-
rating symptoms of physiological response to stress, including
inflammation of the mucous membranes, discomfort and stiff-
ness associated with osteoarthritis disorders, and bone
loss [8, 18].
Clinical Studies
Most recently, published clinical researches have demonstrat-
ed CF’s ability to modulate key markers associated with the
body’s inflammatory response mechanism. In particular, the
studies indicate that CF significantly modulates elevated se-
rum levels of C-reactive protein (CRP) in humans and some
cytokines.
Clinical Study No. 1
A double-blind, placebo-controlled study was performed on
healthy volunteers, 10 subjects per group [4]. CF supplemen-
tation tested over a 14-day period at a serving of 108 mg
(2.91 mg B and 5.4 mg Ca) twice per day [4]. CRP was
reduced by 37 % versus baseline, pre-supplementation value.
CF also induced a 19 % increase in endogenous levels
of calcitriol, the active form of vitamin D3 (1,25-
dihydroxyvitamin D). Blood level of CRP in 7 out of 10 sub-
jects was found reduced up to 37 % compared to day 1 base-
line levels. Interestingly, the study also showed that blood
level of endogenous vitamin D3 was increased more than
19 % compared to baseline [4].
Clinical Study No. 2
A double-blind, placebo-controlled study evaluated the effect
of CF on systemic inflammation and dyslipidemia markers for
middle-aged people with primary osteoarthritis, 15 subjects
per group [29]. CF supplementation tested over a 14-day pe-
riod at a serving of 57 mg per day (1.5 mg B and 2.85 mg Ca).
CRP was reduced by 60.25 % versus baseline, pre-
supplementation value. The CF group also experienced a re-
duction in elevated levels of erythrocyte sedimentation rate
(−10.25 %) and fibrinogen (−13.73 %), other common mea-
sures of inflammation. This study also provides important
information regarding the possible molecular mechanisms of
an anti-inflammatory compound with an identical natural or-
igin in the nutrition of osteoarthritis (OA) demonstrated that
CF has potential efficacy in terms of reducing pain and im-
proving the physical ability of OA patients. Summing up, the
presented data have important implications for new strategy
development for preventing OA and dyslipidemia associated
with fructoborate supplementation [29].
Clinical Study No. 3
A double-blind, active-controlled (existing treatment proto-
col) study has been achieved on patients with stable angina
pectoris, 29 subjects per group [6]. CF supplementation tested
over a 60-day period at a serving of 112 mg once per day
(3 mg B and 5.26 mg Ca). CRP was reduced by 39.7 % versus
baseline, pre-supplementation value. The CF group also ex-
perienced benefits on other clinical endpoints, including a
5.9 % reduction in total cholesterol, a 9.2 % reduction in
LDL (low-density lipoprotein) cholesterol, a 5.1 % increase
in HDL (high-density lipoprotein) cholesterol, and a 48.8 %
reduction in angina episodes per week. In this study, high-
sensitivity (hs)-CRP and pro-BNP (pro-hormone brain
natriuretic peptide) showed significant changes in a relatively
short time (2 months). This finding opens new directions of
research regarding the use of natural adjuvants (CF plus res-
veratrol) for improving the standard anti-angina therapies [6].
Clinical Study No. 4
A double-blind, placebo-controlled clinical study has been de-
signed to determine the effects of CF on levels of CRP, total
cholesterol (TC), LDL cholesterol, triglycerides, interleukin-
1β (IL-1β), interleukin-6 (IL-6), and MCP-1 (monocyte
chemoattractant protein-1) [7]. The objective of this study
was to investigate whether CF alters blood levels of lipids,
homocysteine, CRP, IL-1β, IL-6, and MCP-1 in generally
healthy middle-aged subjects in order to evaluate the potential
use of CF as a dietary supplement to support cardiovascular
health. Our results suggest that use of CF at a daily dose as low
as 112 mg for 30 days may significantly reduce levels of the
pro-inflammatory and pro-atherogenic markers TC, LDL cho-
lesterol, triglycerides, CRP, and homocysteine, while increas-
ing the levels of HDL cholesterol, which is considered a pro-
tective lipid. Furthermore, supplemental use of CF at a dose of
112 mg per day (3 mg B and 5.26 mg Ca) appears to have a
statistically significant inhibitory effect on pro-inflammatory
cytokines such as IL-1β, IL-6, andMCP-1. In humans, plasma
levels of MCP-1 correlate with the severity of cardiovascular
conditions. Several researchers have postulated that blocking
or reducing the expression of MCP-1 might be beneficial in
preventing the development of unhealthy heart conditions [7].
Clinical Study No. 5
A comparative, double-blind, placebo controlled acute clinical
study has been designed to show the effects of calcium
fructoborate short-term use in combination with chondroitin
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sulfate and glucosamine on improvement of knee discomfort
conditions and physical mobility of the joints in healthy sub-
jects [30]. There were three groups involved in the study of
joint discomfort: the first one was treated with a blend of
750 mg glucosamine and 200 mg chondroitin sulfate, the sec-
ond one was treated with a blend of 750 mg glucosamine,
200 mg chondroitin sulfate, and 110 mg calcium fructoborate
(3 mg B and 5.4 mg Ca), and the third group was placebo
(160mg of fructose and 30mg of silica oxide). Treatment with
glucosamine combinedwith chondroitin sulfate and CF result-
ed in a statistically significant 24 % reduction of mean
WOMAC score and a 25 % reduction of mean McGill index
at day 14 over baseline (p=0.0006 and p<0.0001, respective-
ly). Treatment with placebo or with glucosamine and chon-
droitin sulfate did not result in significant improvement of the
conditions. The final result of this study clearly indicate that
short-term use of CF in combination with chondroitin sulfate
and glucosamine was effective in reducing knee discomfort
and improving the joints’ physical mobility [30].
Mechanism of Action of Calcium Fructoborate
It is known that at the cell pH of 7.4, boron (B) is connected
with fructose only as free boric acid and fructoborate esters
and not as anion borate (this is because fructoborates pKa is
4.16) [18]. Overall, there are scientific data about a more gen-
eral function for B, where B cross-links glycoproteins in cell
membranes [31]. Subsequently, the most probable action
mechanism of CF may be the chemical bonding of
fructoborate to specific cytokines glycoproteic receptors at
the surface of the cellular membrane. This may be happening
since the fructoborate pKa (4.16) is lower than the cellular pH
(7.4), compared with the boric acid whose pKa (9.24) is higher
than the cellular pH. Consequently, fructoborate has a better
interaction capacity with glycoproteins versus that of the boric
acid/borate. Furthermore, the free boric acid generated by hy-
drolysis of the fructoborate complex was recently shown to
crystallize in the hexagonal system rather than in the triclinic
system as compared to the regular boric acid [32]. These dif-
ferent ways of crystallization may influence toxicity and bio-
logical activity of the free boric acid. This hypothesis is being
currently investigated in our laboratory. Accordingly, the
fructoborate complex is a non-toxic boron Breservoir^ [33].
Our consideration is that fructoborate complex has physiolog-
ical activity both within the cell (as free boric acid) and also
outside of the cell (as fructoborates).
Conclusions
The three-borate forms contained by the hydrolyzed calcium
fructoborate (diester, monoester, and boric acid) are all
biologically active, both at the intracellular (boric acid) and
extracellular levels (diester and monoester). Transportation of
the boric acid through the cellular membrane is being accom-
plished by free diffusion or is facilitated by aquaporin-like
protein transporter. Recently, it has been reported that boron
is not being transported as borate anion [34], but only as boric
acid. If so, the exact mechanism of boron transportation in the
animal cell remains unclear [35–37]. Consequently, CF is su-
perior to the boric acid/borate due to its complex action mech-
anism, both at the intracellular (as free boric acid) and extra-
cellular level (as fructose-borate esters). Moreover, the free
boric acid resulting from hydrolysis of the fructoborate com-
plex may be less toxic than the dietary supplement intake of
the regular boric acid/borax/sodium borate. Because CF has
been shown to be an efficient, non-toxic precursor of the bo-
rate anion, having multiple published studies on its numerous
potential contributions to human health, nutritional supple-
mentation with CF offers significant benefits in support of
healthy bone and joints, as well as for cardiovascular health.
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